A software platform for discovering cancer-related neoantigens using RNA sequencing data
Official title: Comprehensive validation and commercial readiness of SpliceIO, a software platform for neoantigen discovery using RNA-seq data
Funded at Envisagenics, INC. · NIH-10647773 · Data updated 2026-11-12
This study is testing a new software called SpliceIO that helps find unique markers in cancer cells caused by mistakes in how RNA is put together, which can lead to better treatment options for patients with cancers like breast and pancreatic cancer.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Envisagenics, INC. NIH-funded |
| Lab location | 1 site (Long Island City, UNITED STATES) |
| Project start | July 1, 2022 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $980,257 |
| NIH project number | 5R44CA265446-02 |
| Project ID | NIH-10647773 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers characterized by low tumor mutational burden, such as breast, prostate, and pancreatic cancers.
✕Less likely to help
Patients with cancers that have high mutation rates or those not affected by splicing errors may not benefit from this research.
What this research studies
This research focuses on developing and validating SpliceIO, a software platform that identifies neoantigens derived from splicing errors in RNA sequencing data. By analyzing RNAseq data, the platform aims to uncover tumor-specific neoantigens that are often missed by traditional methods that rely on whole-exome sequencing. This approach is particularly beneficial for cancers with low mutation rates, such as breast and pancreatic cancers, where splicing errors are prevalent. The goal is to enhance the development of immunotherapies that can target these neoantigens, potentially improving treatment options for patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies tailored to patients with low tumor mutational burden.
How similar studies have gone: Other research has shown promise in using RNA sequencing for neoantigen discovery, but the specific approach of focusing on splicing errors is relatively novel.
Where this research is happening
-
Envisagenics, INC.
Long Island City, United States Active
Researchers
- Principal investigator: Akerman, Martin — Envisagenics, INC.
- Study coordinator: Akerman, Martin
Related research
Other NIH-funded projects on the same topics.
-
SpliceDisco: A ML tool to find cancer splice targets for therapy
A new AI tool helps identify cancer-spanning splice events that could be targeted by immune-based therapies, focusing on breast cancer and other cancers.
-
A software platform for discovering cancer-related neoantigens using RNA data
This study is testing a new software called SpliceIO that helps find unique markers in certain cancers, like breast and prostate cancer, by looking for mistakes in RNA, which could lead to better and more personalized treatments for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.